News >

Frontline Osimertinib Extends PFS in EGFR+ NSCLC

Jason Harris
Published: Thursday, Jul 27, 2017

Sean Bohen, MD, PhD

Sean Bohen, MD, PhD
Frontline osimertinib (Tagrisso) significantly improved progression-free survival (PFS) versus standard of care in patients with locally-advanced or metastatic EGFR-positive non–small cell lung cancer (NSCLC), according to results from the phase III FLAURA trial.

Grade ≥3 AEs were reported in 23% of the osimertinib group versus 47% of the chemotherapy arm. The most frequently reported grade ≥3 events in the chemotherapy arm were neutropenia (12%), anemia (12%), and thrombocytopenia (7%). The incidence of each of those toxicities in the osimertinib arm was 1% or less.


  1. Ramalingam S, Yang JC, Lee CK, et al. Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two phase I expansion cohorts. Presented at: 2016 European Lung Cancer Conference; April 13-16, 2016; Geneva, Switzerland. Abstract LBA 1.
  2. Mok TS, Wu YL, Ahn MJ, et al. The AURA3 Investigators. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017; 376:629-640.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication